1997 Royal College mealist in medicine

August 1997
Clinical & Investigative Medicine;Aug97 Supplement, Vol. 20, pS112
Academic Journal
Presents an abstract of the research manuscript `Experimental investigation of levodopa-induced dyskinesia in a primate model of Parkinsonism,' by P.J. Blanchet.


Related Articles

  • Actions of the D[sub 1] agonists A-77636 and A-86929 on locomotion and dyskinesia in MPTP-treated L-dopa-primed common marmosets. Pearce, R. K. B.; Jackson, M.; Britton, D. R.; Shiosaki, K.; Jenner, P.; Marsden, C. D. // Psychopharmacology;1999, Vol. 142 Issue 1, p51 

    Abstract Common marmosets show parkinsonian motor deficits following 1-methyl-4-phenyl-l,2,3,6-tetrahydropyridine (MPTP) administration and develop dyskinesias during chronic L-dopa exposure. The D[sub l] agonists A-77636 [(1R, 3S) 3-(l'-adamantyl)-l-aminomethyl-3, 4-dihydro-5,...

  • Resolution of dyskinesia and the 'on-off' phenomenon in thyrotoxic patients with Parkinson's disease after antithyroid treatment. Caradoc-Davies, T.H. // British Medical Journal (Clinical Research Edition);7/5/1986, Vol. 293 Issue 6538, p38 

    Investigates the dyskinesia and the 'on-off' phenomenon in thyrotoxic patients with Parkinson's disease after antithyroid treatment. Difficulty of diagnosing thyrotoxins; Complications of treatment with compounds containing levodopa; Response of patients to the thyrotrophin releasing hormone...

  • Chronic bilateral pallidal stimulation and levodopa do not improve gait in the same way in Parkinson's disease: a study using a video motion analysis system. Krystkowiak, Pierre; Blatt, Jean Louis; Bourriez, Jean Louis; Duhamel, Alain; Perina, Myriam; Kemoun, Gilles; Blond, Serge; Guieu, Jean Daniel; Dest�e, Alain; Defebvre, Luc // Journal of Neurology;Nov2001, Vol. 248 Issue 11, p944 

    Chronic bilateral internal globus pallidus (GPi) stimulation allows control of levodopa induced dyskinesias (LID) and motor symptoms in severe Parkinson's disease (PD). The effect on gait has not been clearly established. Different results have been reported, mostly consisting of clinical data....

  • New Insights About Impulse Control Disorders in Parkinson's Disease. Nirenberg, Melissa J. // Neurology Alert;Apr2011, Vol. 29 Issue 8, p63 

    LEVODOPA AND DOPAMINE AGONISTS ARE HIGHLY EFFECTIVE treatment for Parkinson's disease (PD) and alleviate many of the disabling motor and non-motor disease manifestations. Over time, however, patients begin to develop motor and behavioral complications of chronic dopaminergic therapy. Motor...

  • Tolcapone increases maximum concentration of levodopa. Müller, T.; Woitalla, D.; Schulz, D.; Peters, S.; Kuhn, W.; Przuntek, H. // Journal of Neural Transmission;Jan2000, Vol. 107 Issue 1, p113 

    Summary. No significant increase of the maximum concentration (Cmax) of levodopa after addition of catechol-O-methyltransferase inhibitor tolcapone occurred in previous pharmacokinetic studies predominantly on healthy volunteers. We compared pharmacokinetics of levodopa in plasma before and...

  • Use of the new levodopa agent Stalevo (levodopa/carbidopa/entacapone) in the treatment of Parkinson's disease in out-patient clinical practice (the START-M open trial). Boiko, A. N.; Batysheva, T. T.; Minaeva, N. G.; Babina, L. A.; Vdovichenko, T. V.; Zhuravleva, E. Yu.; Shikhkerimov, R. K.; Malykhina, E. A.; Khozova, A. A.; Zaitsev, K. A.; Kostenko, E. V. // Neuroscience & Behavioral Physiology;Nov2008, Vol. 38 Issue 9, p933 

    Despite the significant symptomatic effects of levodopa, stable 24-h treatment responses are in the vast majority of patients replaced 2–3 years from the start of treatment by oscillations in motor symptoms (fluctuation, dyskinesia), amelioration of which requires addition of constant...

  • Which factors influence therapeutic decisions in Parkinson's disease? Baas, H.; Fuchs, G.; Gemende, I.; Hueber, R.; Lachenmayer, L.; Schneider, E.; Schoenberger, B.; Werner, M. // Journal of Neurology;Dec2002 Supplement 3, Vol. 249, piii49 

    Development of dyskinesia is a common phenomenon during the long-term course of Parkinson's disease. During the last few years, some but not all pathogenetic mechanisms causing dyskinesias in PD have become better understood. Severity of Parkinson's disease and levodopa dosing are the main...

  • Entacapone. Holm, Kristin J.; Spencer, Caroline M. // Drugs;Jul1999, Vol. 58 Issue 1, p159 

    Entacapone is a potent and specific peripheral catechol-O-methyltransferase (COMT) inhibitor. It has been shown to improve the clinical benefits of levodopa plus an aromatic L-amino acid decarboxylase inhibitor (AADC) when given to patients with Parkinson's disease and end-of-dose deterioration...

  • Long term motor complications of levodopa: clinical features mechanisms, and management strategies. Thanvi, B. R.; T. C. N. Lo // Postgraduate Medical Journal;Aug2004, Vol. 80 Issue 946, p452 

    Levodopa is the most effective symptomatic treatment of Parkinson's disease. However, after an initial period of dramatic benefit, several limitations become apparent including, dopa resistant motor symptoms (postural abnormalities, freezing episodes, speech impairment), "dopa resistant"...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics